NEW YORK (GenomeWeb News) – Co-Diagnostics and DNA Logix have created a joint venture to tackle infectious diseases in high-burden developing countries.
The venture, called Co-Diagnostics HBDC, will sell testing products and services based on PCR testing technology developed by DNA Logix to HBDCs. Co-Diagnostics HBDC is licensing the technology specifically for the HBDC market.
While HBDCs have 90 percent of the burden of disease globally, just 10 percent of R&D is devoted to them, the partners said. And while DNA testing is recommended for the rapid and accurate diagnosis for diseases such as tuberculosis, the cost has prohibited its use in many countries, Co-Diagnostics and DNA Logix said.
"There is a lot of unmet need in the world," Brent Satterfield, CEO of DNA Logix, said in a statement, "and we believe that innovative testing technologies, combined with forward-thinking business models will allow us to reach a much larger number of people."